Keytruda Product Familiarisation Program
A new Keytruda (pembrolizumab) Product Familiarisation Program (PFP) is now open for healthcare professionals to gain experience with the use of Keytruda, in combination with enfortumab vedotin, for the first-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma (LA/mUC).
For more information, access:
- Healthcare Professional Guide for full inclusion criteria and program details
- Patient Information & Consent form
Eligible prescribers may enrol up to 10 patients.
The PFP is open for enrolment and will remain open until 31 May 2026, or until Keytruda is listed on the PBS for this indication, or until the program reaches its maximum patient enrolment (whichever happens first).
Keytruda will be supplied free of charge during the program until the maximum treatment duration is reached (24 months) or the patient experiences disease progression, or until PBS listing for this indication, whichever comes first
Agents used in combination with Keytruda should be obtained through the usual channels and are not supplied or reimbursed by MSD
HCPs can contact their state-based Oncology Portfolio Manager for support:
|
Name |
State |
|
Mobile |
|
Jonathan Wallen |
QLD & Northern NSW |
+61 (414) 795 137 |
|
|
Louise Fenton |
QLD |
+61 (414) 795116 |
|
|
Shajyy Rifat |
NSW & ACT |
+61 (414) 795 553 |
|
|
Dominic Taafe |
VIC & TAS |
+61 (413) 875 658 |
|
|
Carol Katsabiris |
VIC |
+61 (414) 795 118 |
|
|
Alexis Ong |
SA, NT & WA |
+61 (414) 795 167 |